Document:

Form of Performance Unit Agreement

 Exhibit 10.8 
  
 PERFORMANCE UNIT AGREEMENT 
  
                                     , Amgen Inc.
Grantee: 
  
 On this      day of
                         (the “Grant Date”), Amgen Inc., a Delaware corporation (the
“Company”), pursuant to its Performance Award Program (the “Program”) which implements the Amended and Restated 1991 Equity Incentive Plan (the “Plan”), has granted to you, the grantee named above,
                         performance units (the “Units”) on the terms and conditions set forth in this
Performance Unit Agreement (this “Agreement”), the Plan, the Program and the Resolutions (as defined below). Capitalized terms not defined herein shall have the meanings assigned to such terms in the Program. 
  
 I. Performance Cycle. The Performance Cycle shall begin on January 1,
200   and end on December 31, 200  . 
  
 II. Value of Units. The value of each Unit is equal to the closing price of a share of Common Stock on the Grant Date. 
  
 III. Performance Goals. Up to 225% of the Units shall be earned, depending on the extent to which the Company achieves objectively determinable
performance goals established by the Compensation and Management Development Committee (the “Committee”) pursuant to those certain Resolutions of the Compensation and Management Development Committee of the Board of Directors of
Amgen Inc., adopted on             , regarding the Performance Award Program (the “Resolutions”). The Units earned shall be calculated in accordance with the
Resolutions and the Program. 
  
 IV. Form and Timing of
Payment. Subject to Section X and except as set forth in the Program, any Units earned pursuant to Section III above shall be paid as soon as practicable following the Determination Date in shares of Common Stock based on a 30-day average
trading price of the Common Stock ending seven trading days immediately preceding the Determination Date. Shares of Common Stock issued in respect of a Unit shall be deemed to be issued in consideration of past services actually rendered by you to
the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.

  
 V. Issuance of Certificates; Tax Withholding. All
payments made pursuant to Section IV above shall be subject to withholding of all applicable taxes, based on the minimum statutory withholding rates for federal, state and local tax purposes, including any employment taxes resulting from the vesting
of the Units (the “Tax Obligations”). You hereby agree that you will satisfy the Tax Obligations resulting from the vesting of the Units by authorizing, and you hereby authorize, the Company to withhold from the shares of Common
Stock otherwise deliverable to you as a result of the vesting of the Units in accordance herewith, a number of shares having a fair market value less than or equal to the Tax Obligations. Any shares of Common Stock withheld by the Company hereunder
shall not be deemed to have been 
  

 1 

 issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder. The number of
shares of Common Stock tendered by you pursuant to this subsection shall be determined by the Company and be valued at the fair market value of the Common Stock on the date the Tax Obligations arise. To the extent that the number of shares tendered
by you pursuant to this subsection is insufficient to satisfy the Tax Obligations, you hereby authorize the Company to deduct from your compensation the additional amount necessary to fully satisfy the Tax Obligations. If the Company chooses not to
deduct such amount from your compensation, you agree to pay the Company, in cash or by check, the additional amount necessary to fully satisfy the Tax Obligations. You agree to take any further actions and execute any additional documents as may be
necessary to effectuate the provisions of this Section V. Notwithstanding Section IV above, no certificates representing the shares of Common Stock shall be delivered to you unless and until you have satisfied your obligations with respect to the
full amount of all federal, state and local tax withholding or other employment taxes applicable to you resulting from the payment of the Units earned. 
  
 VI. Nontransferability. No benefit payable under, or interest in, this Agreement or in the shares of Common Stock that may become issuable to you
hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or
subject to, your or your beneficiary’s debts, contracts, liabilities or torts; provided, however, nothing in this Section VI shall prevent transfer (i) by will, (ii) by applicable laws of descent and distribution or (iii) to an Alternate
Payee to the extent that a QDRO so provides, as further described in the Program. 
  
 VII. No Contract for Employment. This Agreement is not an employment or service contract and nothing in this Agreement shall be deemed to create in any way whatsoever any obligation on your part to continue in
the employ or service of the Company, or of the Company to continue your employment or service with the Company. 
  
 VIII. Notices. Any notices provided for in this Agreement or the Plan shall be given in writing and shall be deemed effectively given upon receipt
or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at such address as is currently maintained in the Company’s records or at such other address as
you hereafter designate by written notice to the Secretary of the Company. 
  
 IX. Resolutions, Plan and Program. This Agreement is subject to all the provisions of the Resolutions, the Plan and the Program and their provisions are hereby made a part of this Agreement and incorporated
herein by reference, including without limitation the provisions of Sections 7 and 10(d) of the Plan (relating to stock bonuses) and Section 11 of the Plan (relating to adjustments upon changes in the Common Stock), and is further subject to all
interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of this Agreement and those of the Resolutions, the Plan and the
Program, the provisions of the Plan shall control. Notwithstanding any provision of this Agreement or the Program to the contrary, any earned Units paid in cash rather than shares of Common Stock shall not be deemed to have been issued by the
Company for any purpose under the Plan. 
  

 2 

 X. No Compensation Deferral. The Units are not intended to constitute “nonqualified deferred
compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). However, if at any time the Committee determines that the Units may be subject to Section 409A, the Committee shall
have the right, in its sole discretion, and without your prior consent to amend the Program as it may determine is necessary or desirable either for the Units to be exempt from the application of Section 409A or to satisfy the requirements of
Section 409A, including by adding conditions with respect to the vesting and/or the payment of the Units, provided that no such amendment may change the Program’s “performance goals,” within the meaning of Section 162(m) of the Code,
with respect to any person who is a “covered employee,” within the meaning of Section 162(m) of the Code. Any such amendment to the Program may in the Committee’s sole discretion apply retroactively to this award of Units. 

 
 XI. Provisions Applicable to Participants in Foreign Jurisdictions.
Notwithstanding any provision of this Agreement or the Program to the contrary, if you are employed by the Company or its Affiliates outside the United States or are subject to the laws of any foreign jurisdiction, your award of Units shall be
subject to the following additional terms and conditions: 
  
 (a)
the terms and conditions of your award of Units are deemed modified to the extent necessary to comply with applicable foreign laws; 
  
 (b) if applicable, the effectiveness of your award of Units is conditioned upon its compliance with any applicable foreign laws, regulations, rules or
local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals; 
  
 (c) to the extent necessary to comply with applicable foreign laws, the payment of any earned Units shall be made in cash or Common Stock, at the
Company’s election; and 
  
 (d) the Committee may take any
other action, before or after an award of Units is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals. 
  
 Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no award of Units shall be granted, that would violate
the Securities Act of 1933, as amended (the “Act”), Securities Exchange Act of 1934, as amended, the Code, or any other securities or tax or other applicable law or regulation. Notwithstanding anything to the contrary contained
herein, the shares issuable upon vesting of the Unit shall not be issued unless such shares are then registered under the Act, or, if such shares are not then so registered, the Company has determined that such exercise and issuance would be exempt
from the registration requirements of the Act. 
  

 3 

 XI. Governing Law. This Agreement shall be construed and interpreted, and the rights of the
parties shall be determined, in accordance with the laws of the State of Delaware, without regard to conflicts of law provisions thereof. 
  

			
	 Very truly yours,

	 AMGEN INC.

	
	 By:                                      
                                        
  

	 Name:
	 	 
	 Title:
	 	 

  
 Accepted and Agreed, 

this      day of
                    , 2005. 
  

			
	 By:                                      
                                        
  

	 Name:
	 	 

  

 4LETTER AGREEMENT

 Exhibit 10.32 
  
 November 18, 2004 
  
 Mr. Gideon Argov 
 99 Lincoln Street 
 Newton Highlands, MA 02461 
  
 Dear Gideon; 
  
 On behalf of the Board of
Directors of Mykrolis Corporation (the “Board”), it is my pleasure to extend this revised offer to you to join Mykrolis Corporation as its Chief Executive Officer, in accordance with our discussion of this morning. We are very enthusiastic
about your joining Mykrolis and I trust that you will find the following offer to be acceptable. 
  

			
	 Position:
	 	Chief Executive Officer, reporting directly to the Board. Effective with your commencement of employment, you will also be elected to the Board as a Class III Director. Thereafter, you will
be nominated for election to the Board as a member of management’s slate at each annual meeting of stockholders at which Class III Directors come up for election. As a management director you will not be entitled to any compensation for your
service as a director of Mykrolis.
	
	 As Chief Executive Officer you shall have those powers and duties of the Chief Executive Officer enumerated in the By-Laws of Mykrolis Corporation as
well as the powers and duties customary to chief executive officers of publicly held corporations.

	
	 Compensation:

		
	Base Salary:	 	 Four Hundred and Fifty Thousand Dollars ($450,000) per year, paid biweekly.

		
	Incentive Compensation:	 	Commencing with calendar year 2006, you will participate in the Mykrolis Incentive Plan (MIP) at an award level of 70% of base salary at target performance achievement. Awards under the MIP
are currently scaled to Mykrolis’s performance against budget with threshold performance qualifying for 0.5 times target and maximum performance qualifying for 3.0 times target so that, as an illustration of your case using the current award
formula, the possible awards would range from $0 for below threshold performance to $945,000 for maximum performance. The Management Development & Compensation Committee of the Board reviews the MIP award formula annually so that your MIP
participation in 2006 will be under the award formula adopted by that Committee for 2006, provided, that your award level shall not be less than 70% of base salary for that year at target performance.

  

 Exhibit Volume Page 4 of 84 

			
	Equity Compensation:	  	In lieu of a MIP award for 2005, a restricted stock award of 50,000 shares of Mykrolis Common Stock or equivalent will be made effective with your commencement of employment. The restrictions
will lapse as to 12,500 shares on each anniversary of your date of employment.
		
	 	  	A grant of a stock option covering 450,000 Mykrolis shares will be made effective with your commencement of employment. This option will vest 25% on the first anniversary of the date of grant
and quarterly thereafter in twelve equal installments and will carry a seven-year life in accordance with terms of the Mykrolis standard option grant agreement. You understand and agree that you will not be eligible for further equity compensation
until the annual management equity compensation award in December of 2006.
		
	 Benefits:
	  	All Benefit Coverage provided the most senior executives of Mykrolis effective immediately upon your commencement of employment. These benefits will include, but not be limited to,
participation in the Mykrolis Supplemental Executive Retirement Plan and in the short and long term disability plans, which currently generally afford STD benefit coverage of 70% of base salary for six months and LTD benefit coverage of 60% of such
base salary until return to work or, if the disability is permanent, life. Attached is the Mykrolis Benefit Highlighter outlining all the benefit programs offered by Mykrolis. If you wish more detailed information, please contact Mykrolis’s
General Counsel, Peter Walcott at (978) 436-6680.
		
	 Employee-at-Will:
	  	As is the case with your predecessor and all Mykrolis employees, you will be an employee-at-will. However, Mykrolis will enter into its standard forms of Indemnification Agreement and
Executive Termination Agreement (change of control agreement) with you. Further, in the unlikely event that you are terminated for any reason other than Cause or that you resign for Good Reason as such terms are defined in and subject to the terms
and conditions of the Separation Agreement attached hereto as Annex A, you shall be entitled to the severance benefits specified therein.
		
	 Starting Date:
	  	We would welcome your starting in this position full time on November 22, 2004, on which date we would expect to make a public announcement of your appointment. Of course, should you wish to
meet with Mykrolis management on a confidential basis prior to that date, they will be available to you as their schedules permit. Please co-ordinate this through Peter Walcott.
		
	 Legal Fees:
	  	Mykrolis agrees to pay one-half of the first $6,000.00 of your reasonable attorneys’ fees in connection with negotiating

  

 Exhibit Volume Page 5 of 84 

			
	 	  	and revising this offer letter including the attached separation agreement and reviewing the Executive Termination Agreement and the Indemnification Agreement.
		
	 Board Action:
	  	Of course, your election to the above positions and the grant/award of the equity compensation described above are subject to formal action by the Board of Directors on or before November 22,
2004. However, all members of the Board are fully informed as to the terms of this offer so I anticipate no difficulty in obtaining approval.
		
	 Regulatory Matters:
	  	As the Chief Executive Officer of Mykrolis you will, of course, be subject to the reporting requirements of Section 16(a) of the Securities Exchange Act of 1934. We would expect to issue a
press release announcing your appointment and to file a Form 8-K Report with the S.E.C. describing the terms of this offer promptly after your election. In addition, since a portion of the equity compensation specified above will be issued under the
Mykrolis 2003 Employment Inducement and Acquisition Stock Option Plan, the details of your equity compensation will be described in the press release announcing your appointment and will be noticed to the New York Stock Exchange in accordance with
Exchange rules. Further, as the Chief Executive Officer of Mykrolis at the time that it files its Form 10-K Annual Report for fiscal year 2004 with the S.E.C., you will be expected to sign that report as well as the certificates required of the
Chief Executive Officer by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.

  
 Please evidence your acceptance of
this offer by forwarding a countersigned copy of this letter to me c/o Peter W. Walcott at Mykrolis’s headquarters. We are hoping for a response by November 19, 2004. 
  
 Again, I express my sincere congratulations and enthusiasm. I believe you will lead Mykrolis to the next level and I look forward to working
with you in that endeavor. 
  

	
	Sincerely;
	
	 /s/ C. William Zadel

	C. William Zadel
	Chairman of the Board and Chief Executive Officer

  
 I accept the terms and conditions of
this offer. 
  

			
	 /s/ Gideon Argov

	  	Date: 11/18/2004
	Gideon Argov	  	 

  

 Exhibit Volume Page 6 of 84 

 Annex A 
  
 Separation Agreement, dated as of November 21, 2004, by and between Mykrolis Corporation, a Delaware corporation (the “Company”),
and Gideon Argov (“Executive”). 
  
 RECITALS 
  
 1. The Company has
offered Executive employment as its Chief Executive Officer pursuant to an offer letter, dated November 18, 2004 (the “Offer Letter”). 
  
 2. To induce Executive to enter into its employment, the Company is willing to provide Executive with certain severance payments in the event that
his employment terminates under the circumstances described herein. 
  
 NOW, THEREFORE, in consideration of their mutual promises, the Company and Executive agree as follows: 
  
 1. DEFINITIONS. 
  
 1.1. “Cause” means: (i) Executive’s conviction of a felony involving a personal act of willful and intentional misconduct or the entry by
Executive of a plea of nolo contendere in connection with such an alleged felony; (ii) the repeated and continual failure of Executive to fulfill the basic duties of his position with the Company; (iii) Executive’s gross negligence, dishonesty,
willful malfeasance or gross misconduct in connection with his employment with the Company which has had (or is expected to have) a material adverse effect on the business or reputation of the Company or its subsidiaries; or (iv) willful failure by
Executive to follow any lawful directives established for Executive by the Board of Directors. Notwithstanding the foregoing, the deficiencies referred to in clauses (ii), (iii), and (iv) shall constitute Cause only if such deficiency remains
uncured or continues or recurs after ten (10) days notice from the Company specifying in reasonable detail the nature of such deficiency, if such deficiency is capable of cure. 
  
 1.2. “Good Reason” means: (i) failure of the Company to continue the Executive in the position of
Chief Executive Officer or failure of the Board of Directors of the Company to include Executive in the slate of nominees for election as directors after the expiration of Executive’s normal term; (ii) material diminution in the nature
or scope of the Executive’s responsibilities, duties or authority; provided, however, that the Company’s failure to continue the Executive’s appointment or election as a director or officer of any person
directly or indirectly controlling, controlled by or under common control with the Company (“Affiliate”), a change in reporting relationships resulting from the direct or indirect control of the Company (or a successor corporation) by
another corporation and any diminution of the business of the Company or any of its Affiliates or any sale or transfer of equity, property or other assets of the Company or any of its Affiliates shall not constitute “Good Reason”;
(iii) material failure of the Company to provide the Executive with the base salary and benefits in accordance with the terms of the Offer Letter, excluding an inadvertent failure which is cured within ten business days following notice from
the Executive specifying in detail the nature of such failure; or (iv) material breach by the Company of its obligations under the Offer Letter or of the Indemnification Agreement or Executive Termination Agreement referred to therein.
Notwithstanding the foregoing, the deficiencies referred to in clauses (i) and (iv) shall constitute 
  

 Exhibit Volume Page 7 of 84 

 Good Reason only if such deficiency remains uncured or continues or recurs after ten (10) days notice from the Executive
specifying in reasonable detail the nature of such deficiency, if such deficiency is capable of cure. 
  
 2. Termination of Employment by the Company. If the Company terminates Executive’s employment for any reason other than Cause (and
other than as a result of death or disability) or if Executive resigns from the Company for Good Reason, the Company will pay Executive a severance benefit in an amount equal to Executive’s annual base salary as in effect immediately prior to
such termination or resignation. Such severance benefit shall be paid in the form of salary continuation for a period of one (1) year. In addition, the Company will continue healthcare benefits for Executive and his immediate family for one year
following the date of termination or resignation hereunder. 
  
 3. Release. Payment of any benefits under this Separation Agreement shall be subject to and expressly conditioned upon Executive executing a release in favor of the Company in form and substance satisfactory to the Company.

  
 4. Confidentiality. During the period that he is
receiving severance benefits hereunder and for a period of two years thereafter, Executive shall hold all confidential information of the Company in his possession in strict confidence and shall not disclose it to any third party. This
non-disclosure obligation shall not apply to information which is in the public domain, subsequently comes into the public domain through no fault of the Executive, Executive is required to disclose by law and has given the Company reasonable prior
notice thereof, or was known to Executive prior to his employment with the Company. 
  
 5. Public Comment. In the event of Executive’s termination of employment, Executive and the Company each hereby agree not to make any disparaging public statements, including statements by means of
any electronic communication, regarding the other party. The parties shall use their reasonable best efforts to agree on the terms of any public statements to be made regarding the circumstances surrounding Executive’s termination. 

 
 6. Withholding. All payments to be made or benefits to be
provided to Executive in accordance with this Separation Agreement shall be made net of all applicable income and employment taxes required to be withheld from such payments. 
  
 7. Miscellaneous. This Agreement may be amended only by a written instrument signed by the Company and
Executive. Except with respect to any other agreement between the Company and Executive that is specifically referenced herein and intended to continue beyond the execution of this Agreement, this Agreement shall constitute the entire agreement
between the Company and Executive with respect to the subject matter hereof. This Agreement shall be governed by the laws of the Commonwealth of Massachusetts, other than the provisions thereof relating to conflict of laws. This Agreement shall be
binding upon and inure to the benefit of the parties hereto and their respective successors, heirs, executors, administrators (in the case of Executive) and assigns. This Agreement may be executed in counterparts, each of which shall be deemed an
original but all of which together shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, the parties have executed this Separation Agreement effective as of the day first written above. 
  
 MYKROLIS CORPORATION 
  

					
	By:	 	 /s/ C. William Zadel

	  	 /s/ Gideon Argov

	Name, Title:	 	C. William Zadel, Chairman	  	Gideon Argov

  
  

 Exhibit Volume Page 8 of 84

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]